– Total revenues of $919 million in the third quarter
– Jakafi® net product revenues of $636 million in Q3 23, $1.9 billion YTD 2023, driven by growth in total patients across all.
Study finds the biosimilar ABP 654 and ustekinumab do not have clinical meaningful differences according to the step-wide totality-of-evidence approach and thus have similar psychochemical and biological properties.
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024. In July 2023, ANVISA (Agência Nacional de Vigilância Sanitária) granted Market Authoriz
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.